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Edited by Richard MaraisAbstract We have previously shown that Docetaxel-induced
variable degrees of apoptosis in melanoma. In this report, we
studied the b-tubulin repertoire of melanoma cell lines and show
that class III b-tubulin expression correlated with Docetaxel-
resistance. Sensitive cells showed low levels of class III b-tubulin
with little microtubular incorporation, whereas class III b-tubu-
lin expression was higher in resistant cells and was incorporated
into the cytoskeleton. As proof of concept, abrogation of class
III by siRNA reverted Docetaxel-resistant cells to a sensitive
phenotype, restoring the microtubular polymerisation response
and promoting high levels of apoptosis through Bax activation.
These results suggest that phenotypic expression of b-tubulin
class III in melanoma may help identify patients with melanoma
that can respond to taxanes.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Given the pivotal importance of microtubules in many cellu-
lar functions, they have been the targets for anticancer drugs
such as taxanes and vinca alkaloids. By interfering with the
dynamics of microtubule assembly, microtubule-binding
agents exert profound eﬀects on cellular processes such as gene
expression, cell cycle arrest, and apoptosis [1,2]. Taxanes rep-
resent an important class of anticancer agents that have anti-
cancer eﬀects in vitro and in vivo against cancers of lung, ova-
ries, breast, and leukemia [3]. Recently, we have extended these
ﬁndings showing that Docetaxel induces caspase-dependent
apoptosis of some but not all human melanoma cell lines [4].
Resistance of cancer cells to taxanes has been attributed to
various mechanisms including over-expression of (multi-drug
resistance phenotype) P-glycoprotein that induces eﬄux of
the drug [5,6]. Other studies have reported that taxanes mayAbbreviation: MMP, mitochondrial membrane potential
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doi:10.1016/j.febslet.2007.12.014inappropriately induce activation of pro-survival signaling
pathways such as Ras–Raf–MEK–ERK pathway leading to
cancer cell resistance [7–9]. Studies have also shown that alter-
ation in the composition and mutations of b-tubulin isotypes,
can lead to resistance to taxanes [10,11]. Expression of mutant
tubulin or diﬀerential expression of certain tubulin isotypes has
been shown to correlate with the resistance proﬁle of taxane-
resistant cells [10–12]. In some cases, the induced expression
of mutant tubulins [13] and b-tubulin isotypes classes III and
V [14,15] were shown to confer resistance to paclitaxel. Puriﬁed
mutant tubulins also have altered polymerisation characteris-
tics [16] and increased expression of classes I, III, and IVa iso-
types was reported in paclitaxel-resistant cells [10].
In the present study, we have explored the relation between
tubulin isotypes and sensitivity of melanoma cells to Docetaxel
and report that high level of class III b-tubulin can confer
resistance to Docetaxel-induced apoptosis. Moreover, a mech-
anism is suggested by the increased incorporation of class III
b-tubulin into the microtubular network in Docetaxel-resistant
melanoma cells.2. Materials and methods
2.1. Cell lines
The panel of human melanoma cell lines used have been described
previously [17].
2.2. Antibodies and other reagents
Docetaxel (Taxotere), kindly provided by Aventis Pharma S.A
(France), was stored as a 100 mM solution in absolute ethanol at
80 C and diluted immediately prior to use. The polyclonal anti-
Bax antibody was purchased from Upstate Biotechnology (Lake Pla-
cid, NY). The 107.3 mouse IgG1 antibody was purchased from
PharMingen (San Diego, CA). Monoclonal and polyclonal anti-a-
tubulin, classes I, III, and IV b-tubulin and b-actin were purchased
from Sigma–Aldrich (Castle Hill, NSW, Australia).
2.3. Apoptosis
Quantitation of apoptotic cells by measurement of sub-G1 DNA
content using the PI method was carried out as described elsewhere
[18] under conditions established from previous work [4].
2.4. Measurement of tubulin polymerisation
Cytosolic and polymerised fractions of tubulin were separated by
diﬀerential centrifugation as previously described [15]. Brieﬂy cells
were lysed in microtubule-stabilizing buﬀer (20 mM Tris–HCl (pH
6.8), 0.14 M NaCl, 0.5% NP40, 1 mM MgCl2, 2 mM EGTA, and
10 ll/ml protease inhibitor cocktail (Sigma), with 4 lg/ml Docetaxel).
The polymerised fraction was obtained by collecting the supernatantblished by Elsevier B.V. All rights reserved.
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let (polymerised tubulin) was solubilised before electrophoresis in
SDS–PAGE sample buﬀer.
2.5. Indirect immunoﬂuorescence and confocal microscopy
Melanoma cells seeded onto glass coverslips were ﬁxed after the indi-
cated treatments before permeation with 0.1% Triton X-100. After
blocking with 3% bovine serum albumin, cells were immunostained
with primary antibodies before sequential detection with Alexa-488
anti-mouse IgG and or Alexa-594 anti-rabbit IgG (Invitrogen, Austra-
lia). In some experiments nuclei were visualised by DAPI staining. After
mounting in SlowFade Gold reagent cells were examined using a Zeiss
Axioplan 2 epiﬂuorescence microscope or Zeiss Axiovert 100 M ﬁtted
with the LSM510 confocal system (Oberkochem, Germany).
2.6. Flow cytometry and mitochondrial membrane potential (DWm)
Flow cytometric analysis of permeabilised cells for Bax [19] and
mitochondrial membrane using JC-1 staining under established Doce-
taxel treatment conditions as previously described [4].
2.7. Western blot and protein expression analysis
Western blots were performed as described previously [19]. Relative
expression was determined against control proteins (GAPDH or actin)
using densitometric analysis.
2.8. Small RNA interference (siRNA)
Transfections were performed for 48–72 h as previously described [4]
prior to each assay using either SiConTRol Non-targeting SiRNA
pool (D-001206-13-20) or the siGENOME SMARTpool for class III
b-tubulin (TUBB3) siRNA (Dharmacon, Lafayette, CO).
2.9. Cell viability assays
Cell viability assays were performed using the MTT method. After
siRNA treatment cells were seeded at 500 cells/well in 96 well plates
and allowed to adhere overnight before addition of Docetaxel. AfterFig. 1. Docetaxel induces tubulin polymerisation in melanoma cells. (A) So
treated with or without Docetaxel at 20 nM for 3 h and the relative amounts w
(B) Data collected from three individual experiments shown in (A) was analy
also analysed by immunoﬂuorescence microscopy for a-tubulin (green) and n
for (A). bar = 20 lm.a further 72 h 30 ll of 5 mg/ml MTT (3-(4,5-dimethyl thiazolyl-2)-
2,5-diphenyl tetrazolium bromide; Sigma) was added to each well for
2 h. The supernatant was removed, the MTT formazan crystals dis-
solved in 100 ll of DMSO and the optical density read at 550 nm.
2.10. Statistical analysis
The statistical signiﬁcance of intergroup diﬀerences was determined
using Students t-test. P values 60.05 and 60.001 are indicated by *
and **, respectively. Regression analyses were performed using the
StatView program.3. Results
3.1. Docetaxel-resistant melanoma cells have low levels of
polymerized tubulin
Previous studies have shown that Docetaxel binds to the b-
tubulin subunit of the microtubules resulting in their polymer-
isation [20]. We studied the Docetaxel-induced polymerisation
response of microtubules in the IgR3 and MM200 human mel-
anoma cell lines that have been shown previously to be diﬀer-
entially sensitive to this agent [4]. Lysates were prepared from
untreated and Docetaxel treated cells and the samples were
fractionated into soluble and polymerized tubulin fractions
as described in Section 2. Western blotting analysis showed
that under normal growth conditions, MM200 cells have a
lower level of polymerized tubulin compared to IgR3 cells
(Fig. 1A). Densitometric analysis showed that the percentage
of polymerized tubulin before and after treatment with Doce-
taxel was changed from 47% to 86% in IgR3 (P 6 0.05)
whereas a slight increase from 22% to 31% was seen inluble and polymerized fractions of tubulin were separated from cells
ere determined by Western blotting using antibodies against a-tubulin.
sed by densitometry (Columns, mean and bars, S.E.M.). (C) Cells were
uclear staining (DAPI; blue) under the treatment conditions described
Fig. 2. Expression of diﬀerent b-tubulin isotypes in melanoma cells. (A) Total cellular protein from a panel of melanoma cells was subjected to
Western blots for classes I, III, and IV b-tubulins. (B) The relative expression of each class was determined by dividing the densitometric value against
a b-actin control. Columns, mean of three individual experiments; bars, S.E.. (C) Correlation between the relative expression of class III b-tubulin and
the levels of apoptosis induced by 20 nM Docetaxel after 48 h.
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noﬂuorescent staining showing in IgR3 cells that Docetaxel
treatment greatly intensiﬁed the microtubular network. In con-
trast, the microtubular network of MM200 cells was largely
unchanged with Docetaxel treatment (Fig. 1C).
3.2. Human melanoma cells have variable expression of classes
III and IV b-tubulin isotypes
The ability of taxanes to bind and polymerize tubulin was re-
ported to depend upon the expression of speciﬁc b-tubulin iso-
types [21,22]. The expression of various classes of b-tubulin
was examined in a panel of melanoma cell lines by immuno-
blotting. Fig. 2A shows that melanoma cells express classes
I, III, and IV b-tubulin. Expression of class I b-tubulin was
similar between diﬀerent melanoma cells whereas classes III
and IV b-tubulin varied in expression levels (Fig. 2A and B).
Since we have shown previously that Docetaxel induces var-
iable degrees of apoptosis in melanoma cells [4] we examined
whether this variable expression of classes III and IV b-tubulin
tubulin levels correlated with sensitivity to Docetaxel. Fig. 2C
indicates that the expression of class III b-tubulin was inver-
sely correlated with the degree of Docetaxel-induced apopto-
sis. No signiﬁcant correlations were seen between expression
of class IV b-tubulin and Docetaxel-induced apoptosis
(R2 = 0.1699) or with an index considering the combined ef-
fects of class III plus class IV b-tubulin expression versus
apoptosis (data not shown).
Next, we examined the cellular distribution of class III b-
tubulin in both the sensitive IgR3 and the resistant MM200
cells before and after treatment with Docetaxel (Fig. 3). Before
treatment, the staining for class III b-tubulin in the IgR3 cells
revealed a largely cytoplasmic distribution whereas a propor-
tion of class III b-tubulin was clearly incorporated into the
microtubular network in the MM200 cells. Treatment with
Docetaxel caused little alteration in MM200 cells with much
of the class III b-tubulin retained in microtubules. In contrast,Docetaxel caused signiﬁcant disruption of IgR3 cells with class
III b-tubulin localised in membranous blebs and it did not ap-
pear to contribute to the microtubular network. The incorpo-
ration of class III b-tubulin into the microtubular network
therefore appears to phenotypically correlate to the mecha-
nism of melanoma resistance to Docetaxel.
3.3. Silencing of class III b-tubulin sensitized melanoma cells to
Docetaxel-induced apoptosis
The results suggested that resistance of melanoma cells to
Docetaxel-induced apoptosis was due to high expression of
class III b-tubulin. We therefore examined whether modula-
tion of expression levels of class III b-tubulin altered Doce-
taxel-resistance in melanoma cells. As shown in Fig. 4A,
silencing of class III b-tubulin using siRNA inhibited expres-
sion by 79% in MM200 cells compared to the cells transfected
with a control siRNA. Expression levels of classes I and IV b-
tubulins were not aﬀected emphasising the speciﬁcity of the
class III b-tubulin siRNA. Knockdown of class III b-tubulin
expression signiﬁcantly enhanced microtubule polymerisation
(P 6 0.05) and this was accompanied by signiﬁcant increases
in apoptosis induced by Docetaxel (Fig. 4B). This was partic-
ularly dramatic in the MM200 cells reverting these resistant
cells to a sensitive phenotype (P 6 0.001). The increased Doce-
taxel-induced apoptosis observed after class III b-tubulin
silencing was also accompanied by enhanced Bax activation
and increases in mitochondrial membrane potential (MMP)
changes (Fig. 4C; P 6 0.001). Furthermore, class III b-tubulin
siRNA increased the anti-proliferative eﬀects of Docetaxel in
both MM200 and IgR3 cells, reducing the IC50 from 30 to
10.5 nM and 9 to 2 nM respectively (Fig. 4D).
In order to determine if class III b-tubulin transfection could
increase the levels of resistance of IgR3 cells to Docetaxel, we
derived permanent transfectants of these cells over-expressing
class III b-tubulin (Suppl. Fig. 1A). Although these cells dis-
played expression of class III b-tubulin at levels similar to
Fig. 3. Comparative distribution of a-tubulin with class III b-tubulin in IgR3 and MM200 melanoma cells before and after treatment with 20 nM
Docetaxel for 3 h. Results were recorded by dual colour confocal microscopy using monoclonal a-tubulin and class III b-tubulin polyclonal
antibodies, bar = 20 lm.
Fig. 4. Inhibition of class III b-tubulin expression sensitised melanoma cells to Docetaxel-induced apoptosis. (A) MM200 cells were transfected with
control or class III b-tubulin-speciﬁc siRNA (TUBB3) and whole cell lysates subjected to Western blot analysis for classes I, III, IV b-tubulins and a
control protein, b-actin. Data shown are representative of three individual experiments. (B) Measurements of apoptosis and tubulin polymerisation
in siRNA transfected IgR3 and MM200 cells were performed with or without 20 nM Docetaxel treatment after 48 and 3 h, respectively. (C)
Measurements of Bax activation and DWm by JC-1 staining in siRNA transfected IgR3 and MM200 cells were performed after 16–24 h with or
without 20 nM Docetaxol treatment. Data in B and C represent the means ± S.E. of three individual experiments. (D) IgR3 and MM200 cells were
treated with control or TUBB3 siRNA were subjected to the indicated dose titration of Docetaxel. After 72 h cell viability was measured using the
MTT assay. Data were averaged from triplicate determinations and normalised to the control condition, bars, S.E.M.
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Docetaxel in assays measuring apoptosis or cell viability (Sup-
pl. Fig. 1C and D). However permanent transfection of classIII b-tubulin did result in a modest increase in the expression
of a-tubulin (Suppl. Fig. 1B) that may account for this discrep-
ancy (see Section 4).
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In the present study, we have explored for the ﬁrst time the
relationship between microtubular polymerisation, the expres-
sion of tubulin isotypes and the resistance of human melanoma
cell lines to Docetaxel. We have chosen to use a relatively large
panel of cell lines that have diﬀerent intrinsic properties rather
than deriving resistant tumour sublines by selection with
increasingly higher doses of drugs. The latter method is often
used to mimic events that lead to acquired drug resistance
but we believe our approach, which has been far more compre-
hensive than many of the cited studies, may be advantageous
in minimising the likelihood of in vitro artefacts.
The results showed that there was generally a low rate of
tubulin polymerisation in resistant melanoma cells and that
sensitive cells responded by increasing the microtubular mass
whereas resistant cells did not. This result appeared entirely
consistent with the known mode of action of taxanes. Exami-
nation of b-tubulin isotype expression revealed there was very
little variation in class I tubulin expression. Rather the expres-
sion of class III b-tubulin, which varied widely between diﬀer-
ent melanoma cell lines, appeared to be a major determinant of
the degree of tubulin polymerisation and to the resistance to
Docetaxel. This concept was conﬁrmed using an siRNA med-
iated strategy where knockdown of class III b-tubulin en-
hanced Docetaxel-induced tubulin polymerisation, activation
of Bax and downstream apoptotic events that manifested in re-
duced cell proliferation.
In contrast to the results obtained using siRNA against class
III b-tubulin, we were unable to demonstrate that high level
expression of class III b-tubulin by transfection could promote
the resistance of IgR3 melanoma cells to Docetaxel. This
somewhat unexpected result has been previously reported.
For example, transfection of class III b-tubulin into prostate
cancer cells, which is upregulated in these cells by Paclitaxel
exposure, was unable to confer resistance to Paclitaxel and
other microtubule targeting agents [23]. However, it was deter-
mined that stable transfection of class III b-tubulin actually
caused compensatory increases in the expression of a-tubulin
in conjunction with increases in both class II and class IV b-
tubulins. The authors of this work as well as Hari et al. [15]
have both ﬂagged the diﬃculties encountered when using gene
transfection to assay the contribution of individual tubulin iso-
types. The mechanism of the compensatory phenomenon is not
well studied but appears to be acting through transcriptional
regulation [23] and this also appears to be occurring in the
IgR3 cells with a modest increase in a-tubulin expression noted
to occur. We conclude from our study that siRNA is a prefer-
able technique to demonstrate the functional eﬀects on individ-
ual tubulin isotypes. This is probably because its eﬀects
generally occur quite rapidly and its actions are eﬀective
against the entire cell population under treatment.
While our study showed that class III b-tubulin appeared
important in unselected melanoma cell lines, studies in other
types of cancer cell lines have revealed that alterations in b-
tubulins occurs with resistance to microtubule-targeting drugs
although not always associated with a single isotype. For
example, the increased expression of classes III and IVa b-
tubulin has also been associated with the Paclitaxel-resistance
in non-small lung carcinoma cell lines [10] and in K562 eryth-
roleukemia cells [24]. Docetaxel-resistant MCF-7 breast cancer
cells also exhibited increased expression of classes I, II, III andIV b-tubulin isotypes whereas all isotypes examined except for
class IV were decreased in Docetaxel-resistant MB-MDA-231
breast cancer cells [25]. Notwithstanding the diﬀerences ob-
served between various cancer cell lines, increased levels of
b-tubulins do appear to have signiﬁcance for clinical outcomes
with taxanes. Samples of ovarian tumours from patients trea-
ted with Paclitaxel displayed increased levels of classes I, III
and IVa b-tubulins when compared to non-treated patients
[10]. More recently, acquired expression of class III b-tubulin
was not seen in another study of ovarian cancer, however,
the pre-treatment level of this isotype did act as an indepen-
dent prognostic indicator of poor outcome [26]. Similarly, in-
creased expression of classes I and III b-tubulin in breast
[27] and class III b-tubulin non-small cell lung cancer [28] also
appear to predict poor outcomes with Paclitaxel and Doce-
taxel, respectively.
Questions still remain in regard to the mechanism(s) that
underlie the prognostic signiﬁcance of b-tubulin isotypes.
One model proposed by Carbral and colleagues associates
unstable or dynamic microtubules with the resistance of cells
to microtubule targeting agents [29,30]. In accordance, when
class III b-tubulin is assembled into microtubules it has been
reported to result in more unstable microtubules [30] that are
less sensitive to Paclitaxel [31]. In our study we observed that
Docetaxel-resistance in melanoma cells coincided with in-
creased class III b-tubulin incorporation into the microtubular
network. High levels of class III b-tubulin have also been re-
ported to reduce the assembly of microtubules [15] and this
is also consistent with our results measuring the percentages
of microtubular polymerisation. Together these data suggest
that the large monomeric pool of class III b-tubulin acts to
promote dynamic/unstable microtubules that in turn limits
the polymerised microtubular mass in response to Docetaxel.
Towards an understanding of how this process may be regu-
lated, we have recently reported that PKCe is associated with
pro-survival signaling through ERK in melanoma cells treated
with Docetaxel [32]. Moreover PKCe was also shown to co-
immunoprecipitate with cytosolic class III b-tubulin suggesting
it may also be inﬂuencing the incorporation rates of class III b-
tubulin into microtubules.
To our knowledge no clinical data currently exists on the
expression of b-tubulin isotypes in melanoma in vivo. In light
of the work presented here there is now a need determine if
expression of class III b-tubulin can be correlated with tumour
responses in xenograft models and in melanoma patients trea-
ted with taxanes. It will also be important to better understand
the complex mechanisms governing the cellular regulation of
the tubulin repertoire that is clearly very important in deter-
mining how cells respond to taxanes.
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